Lack of a role of interleukin 11 in the growth of multiple myeloma

FDA licensure of neumega® to prevent severe chemotherapy‐induced thrombocytopenia

“…In culture media, NEUMEGAO did not alter the growth of human colonic carcinoma cell lines (data on file). NEUMEGA@ has had either no effect or minor and inconsistent effects on the growth of myeloma cells [52,53] and did not reverse steroid-induced growth arrest in three human myeloma cell lines [54]. NEUMEGAO has no direct effect on acute myelogenous leukemia (AML) cells but has been shown to augment the proliferation of at least some AML cells stimulated by other cytokines [55, 561. In the study by Huwley et al [48], cells from one secondarily transplanted pedigree showed a leukemic phenotype, and a transformed cell line expressing the IL-11 gene was produced from one quarternarily transplanted animal [48].…”

IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation

“…Recombinant human IL-11 (kindly supplied by Genetics Institute Inc., Cambridge, Massachusetts, USA) was diluted in 0.1% BSA in PBS before injection. The protein had a specific activity of 1.6 × 10 6 to 2.1 × 10 6 U/mg, as determined by T10 proliferation assay (19). Mice were injected subcutaneously with IL-11 (250 µg/kg per dose) twice daily, from 2 days before BMT to 7 days after BMT.…”

Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

“…Recombinant human IL-11 was supplied by Genetics Institute (Cambridge, MA) and had a specific activity of 1.6-2.1 ϫ 10 6 U/mg as determined by T10 proliferation assay (17). IL-11 was diluted in 0.1% BSA/PBS before injection.…”